Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Apr 20, 2023 2:17pm

101 Views

Post# 35405774

RE:RE:RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

Exact Eoganacht. ImmunityBio is doing the same thing they did we BCG. Repeating over and over the treatment, over a very long period of time. Our Ph. 1B confirmed that, when we saw how many times our 6 ph. 1b patients had been treated with BCG (9, 11, 24, 24,12,18 times) prior to being declared BCG-Unresponsive and another chance with our treatment.

Number of prior BCG instills

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257636/

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?